Patients with severe asthma receiving mepolizumab experience reductions in healthcare resource use and improvements in work ...

CFO Robert E. Hoffman to deliver company presentation on October 21, 2025 VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a ...

Leap Therapeutics ( ($LPTX) ) has shared an update. On October 6, 2025, Leap Therapeutics entered into a Securities Purchase Agreement for a ...

In what may be one of the most important HIV research breakthroughs in years, scientists have discovered a strikingly ...

The FDA has granted Fast Track designation to Bristol Myers Squibb’s anti-MTBR-tau antibody (BMS-986446) for the treatment of early Alzheimer disease.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an ...

Omalizumab is indicated for the treatment of persistent asthma, chronic rhinosinusitis with nasal polyps, food allergies and ...

In January 2024, LEQEMBI was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as ...

CCR5 inhibition combined with ICI therapy increased overall survival in patients with mTNBC, with 18% of heavily pretreated mTNBC patients alive after a median of ~60 months. Inhibition of CCR5 by ...

Ligufalimab receives FDA orphan drug designation for AML, showcasing promising efficacy and safety in treating hematologic malignancies and solid tumors. The FDA has granted orphan drug designation to ...